アルツハイマー病（AD）患者と健康な被験者を対象としたLY3372993の研究

基本情報

NCT ID

NCT04451408

ステータス

完了

試験のフェーズ

第1相

試験タイプ

介入

目標被験者数

139

治験依頼者名

Eli Lilly and Company

概要

The main purpose of this study is to evaluate the safety and tolerability of LY3372993 in participants with AD, non-Japanese, and Japanese healthy participants who are of first-generation Japanese origin. The study will also investigate how much LY3372993 gets into the bloodstream and will test the effects of LY3372993. The study will be conducted in two parts. The part A includes participants with AD and part B includes healthy participants. Participation could last up to about 61 weeks and may include up to 31 visits to the study center.

対象疾患

介入

依頼者（Sponsor）

実施施設 (3)